DINA 010
Alternative Names: DINA-010Latest Information Update: 01 Mar 2022
Price :
$50 *
At a glance
- Originator DiNAQOR AG
- Class Cardiovascular therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Dilated cardiomyopathy; Hypertrophic cardiomyopathy
Most Recent Events
- 10 Feb 2022 DiNAQOR AG enters a collaboration with the University Medical Centre Hamburg Eppendorf for testing gene therapies, prior to February 2022
- 04 Feb 2022 Early research in Dilated cardiomyopathy in Switzerland (Parenteral) (DiNAQOR AG pipeline, February 2022)
- 04 Feb 2022 Early research in Hypertrophic cardiomyopathy in Switzerland (Parenteral) (DiNAQOR AG pipeline, February 2022)